This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synergy Pharmaceuticals' Chief Scientific Officer To Give Plenary Lecture On Plecanatide And SP-333 At The 15th Annual TIDES Summit

NEW YORK, May 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat patients with gastrointestinal disorders and diseases, today announced its Chief Scientific Officer, Kunwar Shailubhai, Ph.D., M.B.A., will give a plenary lecture on "Plecanatide and SP-333, Guanylate Cyclase-C Agonists: A New Class of Drug Candidates for Treatment of Gastrointestinal Disorders and Diseases," at The 15 th Annual TIDES Summit, May 12-15, at the Hynes Convention Center in Boston, MA.

Guanylate cyclase-C (GC-C) agonists are rapidly emerging as new orally administered drug candidates for treatment of multiple gastrointestinal (GI) disorders and diseases. The lecture will discuss the role of uroguanylin, the natural agonist of GC-C, in the normalization of GI physiology.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal disorders and diseases. Synergy's lead proprietary drug candidate, plecanatide, is a synthetic analog of the natural human peptide hormone, uroguanylin, and functions by activating the guanylate cyclase-C (GC-C) receptor on epithelial cells of the GI tract. Synergy completed positive Phase I and Phase II clinical trials in patients with chronic idiopathic constipation (CIC). Detailed positive findings from its large multicenter trial of plecanatide in patients with CIC are being presented at Digestive Disease Week (DDW) in Orlando, FL and will be published this year. Synergy is also developing plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C), having initiated the first trial in IBS-C patients in late 2012. Synergy's second GC-C agonist, SP-333, is in clinical development for the treatment of ulcerative colitis (UC). The first Phase I trial in healthy volunteers was recently completed. More information is available at http://www.synergypharma.com .

CONTACT: Media Contact:
         Janet Skidmore
         Mobile (during DDW): 215-429-2917
         Office: 215-658-4915
         skidmorecomm@earthlink.net
         
         Investor Contact:
         Danielle Spangler
         The Trout Group
         Office: 646-378-2924
         synergy@troutgroup.com

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs